US4156010A
Expired / Lapsed
US
⏱️ 0.0 years remaining
(R)-(-)-3-{[2-(P-hydroxyphenyl)-1-methylethyl]-aminomethyl}-3,4-dihydro-2H-1,5-benzodioxepin-3-ol
Assignee: Merck and Co Inc
•
Filing: 1977-12-27
•
Granted: 1979-05-22
•
Expires: 1997-12-27
Abstract
Abstract The isomer (R)-(-)-3-{[2-(p-hydroxyphenyl)-1-methylethyl]-aminomethyl}-3,4-dihydr o-2H-1,5-benzodioxepin-3-ol and its non-toxic acid addition salts is unexpectedly more potent in the reduction of elevated interocular pressure in mammals than its enantiomorph or the racemate thereof.
Inventors
- 👤 Ralph F. Hirschmann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 02:28
CPC Classifications
C; C07; C07D; C07D321/00; C07D321/02; C07D321/10
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
37 words
A method of treating glaucoma and of lowering intraocular pressure which comprises topically applying to the eye an intraocular pressure lowering effective amount of (R)-(-)-3-{[2-(p-hydroxyphenyl)-1-methylethyl]aminomethyl}-3,4-dihydro-2H-1,5-benzodioxepin-3-ol or a non-toxic acid addition salt thereof which is free from (S)-(+)-3-{[2-(p-hydroxyphenyl)-1-methylethyl]aminomethyl}-3,4-dihydro-2H-1,5-benzodioxepin-3-ol.
Claim 2
Independent Claim
37 words
A method of treating glaucoma and of lowering intraocular pressure which comprises topically applying to the eye an intraocular pressure lowering effective amount of (R)-(-)-3-{[2-(p-hydroxyphenyl)-1-methylethyl]aminomethyl}-3,4-dihydro-2H-1,5-benzodioxepin-3-ol or a non-toxic acid addition salt thereof which is free from (S)-(+)-3-{[2-(p-hydroxyphenyl)-1-methylethyl]aminomethyl}-3,4-dihydro-2H-1,5-benzodioxepin-3-ol.
Claim 3
Dependent Claim
16 words
A method according to claim 1 wherein the acid addition salt is the hydrogen maleate salt.
Claim 4
Dependent Claim
16 words
A method according to claim 1 wherein the acid addition salt is the dihydrogen phosphate salt.
Claim 5
Dependent Claim
33 words
An ophthalmic composition for the lowering of intraocular pressure comprising an intraocular pressure reducing amount of (R)-(-)-3-{[2-(p-hydroxyphenyl)1-methylethyl]aminomethyl}-3,4-dihydro-2H-1,5-benzodioxepin-3-ol or an acid addition salt thereof and an ophthalmic carrier, which composition is free from (S)-(+)-3-{[2-(p-hydroxyphenyl)-1-methylethyl]aminomethyl}-3,4-dihydro-2H-1,5-benzodioxepin-3-ol.
Claim 6
Dependent Claim
33 words
An ophthalmic composition for the lowering of intraocular pressure comprising an intraocular pressure reducing amount of (R)-(-)-3-{[2-(p-hydroxyphenyl)1-methylethyl]aminomethyl}-3,4-dihydro-2H-1,5-benzodioxepin-3-ol or an acid addition salt thereof and an ophthalmic carrier, which composition is free from (S)-(+)-3-{[2-(p-hydroxyphenyl)-1-methylethyl]aminomethyl}-3,4-dihydro-2H-1,5-benzodioxepin-3-ol.
Claim 7
Dependent Claim
16 words
A composition according to claim 4 wherein the acid addition salt is the hydrogen maleate salt.
Claim 8
Dependent Claim
16 words
A composition according to claim 4 wherein the acid addition salt is the dihydrogen phosphate salt.
Claim 9
Dependent Claim
14 words
The composition of claim 4 wherein the carrier is a solid water soluble polymer.
Claim 10
Dependent Claim
11 words
The composition of claim 4 wherein the carrier is hydroxypropyl cellulose.
Claim 11
Dependent Claim
36 words
An ophthalmologically acceptable water soluble polymeric insert comprising an intraocular pressure lowering effective amount of (R)-(-)-3-[2-p-hydroxyphenyl)-1-methylethyl]aminomethyl-3,4-dihydro-2H-1,5-benzodioxepin-3-ol or an acid addition salt thereof which is free from (S)-(+)-3-[2-(p-hydroxyphenyl)-1-methylethyl]aminomethyl-3,4-dihydro-2H-1,5-benzodioxepin-3-ol in an amount effective to reduce the intraocular pressure.
Claim 12
Dependent Claim
36 words
An ophthalmologically acceptable water soluble polymeric insert comprising an intraocular pressure lowering effective amount of (R)-(-)-3-[2-p-hydroxyphenyl)-1-methylethyl]aminomethyl-3,4-dihydro-2H-1,5-benzodioxepin-3-ol or an acid addition salt thereof which is free from (S)-(+)-3-[2-(p-hydroxyphenyl)-1-methylethyl]aminomethyl-3,4-dihydro-2H-1,5-benzodioxepin-3-ol in an amount effective to reduce the intraocular pressure.
Claim 13
Dependent Claim
15 words
An insert according to claim 9 wherein the acid addition salt is the hydrogen maleate.
Claim 14
Dependent Claim
16 words
An insert according to claim 9 wherein the acid addition salt is the dihydrogen phosphate salt.
References Cited (Backward Citations)
US3700691A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-05-21 | 1982-11-20 | 1983-05-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-05-21 | 1986-11-20 | 1987-05-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-05-21 | 1990-11-20 | 1991-05-22 | $7700.00 | Window Closed / Lapsed |